This week's research shows scientists are attacking IPF (lung scarring disease) from many angles at once — including smarter drug combinations and a deeper understanding of why lung cells stop healing properly.
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
Researchers this week focused heavily on how lung lining cells (the cells that coat the inside of your airways) fail to repair themselves in IPF. Two active research areas — fibroblast biology (studying the scar-forming cells) and epithelial repair (healing the lung's inner surface) — each had 14 new papers. Scientists are also noticing important overlaps between IPF and heart disease, with 20 studies crossing both topics. A study on proton beam therapy for lung cancer patients who also have IPF caught attention, since many IPF patients face this exact situation.
The AI drug-combination solver tested hundreds of treatment mixes. The best result kept lung capacity (FVC — a measure of how much air your lungs can hold) at 69.5%. For context, healthy lungs score around 80% or higher, so this combination meaningfully slows the decline. The seven-drug mix included pirfenidone (already approved), plus newer agents targeting scarring, aging cells, and lung blood vessel health.
One question to ask your lung doctor at your next visit: 'Are there any clinical trials combining pirfenidone with senolytic drugs — medicines that clear out old, damaged cells — that I might qualify for?'